Bioenergetic Effects of Aging and Menopause (BEAM)

Description

The menopause transition is associated with increased risk for weight gain and a shift toward storing fat in the belly region, which may increase risk for cardiovascular disease and diabetes. The study will determine whether the stress hormone cortisol contributes to this shift.

Conditions

Menopause, Obesity, Abdominal, Aging, Weight Gain

Talk to us

Study Overview

On this page

Study Details

Study overview

The menopause transition is associated with increased risk for weight gain and a shift toward storing fat in the belly region, which may increase risk for cardiovascular disease and diabetes. The study will determine whether the stress hormone cortisol contributes to this shift.

Bioenergetic and Metabolic Consequences of the Loss of Ovarian Function in Women - 2018

Bioenergetic Effects of Aging and Menopause (BEAM)

Condition
Menopause
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * abnormal vaginal bleeding
  • * on hormonal contraceptive or menopausal therapy or intention to start during the period of study
  • * positive pregnancy test or intention to become pregnant during the period of study
  • * lactation
  • * known hypersensitivity to degarelix acetate, estradiol, or medroxyprogesterone acetate
  • * Center for Epidemiological Studies Depression Scale (CES-D) score \<,16 (unless clinician follow-up and clinical judgement determine they are eligible (will be noted in study chart)
  • * current tobacco and/or vape use more than 2 times/week
  • * current marijuana or tetrahydrocannabinol (THC) use in any form more than 3 times/week
  • * regular self-reported alcohol consumption \>14 drinks/week
  • * BMI \>39 kg/m2
  • * use of glucocorticoids or drugs that affect glucocorticoid metabolism (e.g., ketoconazole)
  • * severe osteopenia or osteoporosis, defined as femoral neck or lumbar spine t-score \<-2.0
  • * thyroid dysfunction, defined as an ultrasensitive TSH \<0.5 or \>5.0 mU/L; volunteers with abnormal thyroid stimulating hormone (TSH) values will be re-considered for participation in the study after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement
  • * liver dysfunction, defined as liver function tests (AST, ALT) \>1.5 times the upper limit of normal
  • * uncontrolled hypertension defined as resting systolic BP \>150 mmHg or diastolic BP\>90 mmHg; participants who do not meet these criteria at first screening will be re-evaluated, including after follow-up evaluation by the primary care provider (PCP) with initiation or adjustment of anti-hypertensive medications
  • * self-reported history of breast cancer or other estrogen-dependent neoplasms
  • * self-reported history of venous thromboembolism, pulmonary embolism, or other thromboembolic disorder
  • * self-reported history of cardiovascular disease

Ages Eligible for Study

40 Years to 65 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Colorado, Denver,

Wendy M Kohrt, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2024-08-31